Kalbe Farma Tbk PT : to Distribute Dividend of Rp 891 Billion

Kalbe to Distribute Dividend of Rp 891 Billion

Press Release No. 018/KFCP-DIR/PR/V/16

Jakarta, May 31, 2016 - PT Kalbe Farma Tbk ('Kalbe' or 'the Company') will distribute cash dividend of Rp 891 billion. The dividend distribution of Rp 19 per share or equivalent to a dividend payout ratio of around 44% of fiscal year 2015 net income, has been approved by the shareholders of the Company in the Annual General Meeting of Shareholders ('AGMS') held on May 31, 2016 in Gedung Bintang Toedjoe, Pulomas, Jakarta. In compliance with the prevailing regulations, dividend payment will be made at the latest within 30 days after the announcement of AGMS where the Company will shortly announce the schedule and procedures.

'The Company will distribute cash dividend of Rp 891 billion. This reflects our commitment to provide an optimal return to the shareholders,' stated Vidjongtius as the Company's Director and Corporate Secretary. 'Despite the challenging economic condition, we remains confident of the future growth potentials. To support future business expansion, we have allocated budget for capital expenditure for capacity expansion across the board. Taking into account the cash requirement for operational and investment, we will distribute dividend of 44% of 2015 net income to the shareholders. Going forward, we maintain our policy to distribute around 40 - 50% payout ratio, while keeping in mind our financial condition and expansion plan.'

In the AGMS, the Company has also obtained the approval of the shareholders on the following agenda:

1. Approval of the Annual Report of the Company for the year ended December 31, 2015, including the Activity Report of the Company, the Report of the Supervisory Role of the Board of Commissioners, approval and ratification of the Company's Audited Financial Statements for the year ended December 31, 2015 and to grant a release and discharge from their responsibilities to all members of the Board of Commissioners and Board of Directors for their management and supervision actions during the financial year ended December 31, 2015 (acquit et decharge);
2. Approval on the appropriation of the Company's Net Profits for the financial year ended December 31, 2015;

3. Appointment of Independent Public Accountant to audit the Company's Financial Statements for the year ended December 31, 2016 and authorize the Board of Directors to determine the honorarium of the Independent Public Accountant and other appointment's conditions.

4. Determination of salary and/or honorarium of the members of the Board of Commissioners and the Board of Directors and to authorize the Board of Commissioners to determine the salary and/or honorarium of the members of the Company's Board of Commissioners and Board of Directors.
Kalbe at a Glance
PT Kalbe Farma Tbk. ('Kalbe') was established in 1966 and is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions managing a broad and strong portfolio of brands; prescription pharmaceuticals division (Cefspan, Brainact, Broadced, etc), consumer health division comprising over-the-counter drugs (Promag, Mixagrip, Komix, Woods, Fatigon, etc) as well as ready-to-drink and energy drink products (Hydro Coco, Extra Joss, Nitros), nutritionals division (ChilKid, Prenagen, Diabetasol, etc), and distribution division. Kalbe currently has more than 30 subsidiaries and 10 production facilities with international standards, supported by around 16,000 spread in 71 branches across Indonesia. Since 1991, Kalbe's shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).